This week, the Queensland Government announced a pause on access to stage one and stage two hormone therapies for new patients under 18 in the state’s public health system. The decision has raised alarm among healthcare professionals, including the Australian Medical Association and the Royal Australian College of General Practitioners, who warn that it will place already vulnerable young people at greater risk.

The Australian Physiotherapy Association (APA) welcomes the final report of the Scope of Practice Review, Unleashing the Potential of our Health Workforce, which outlines robust solutions to overcoming barriers limiting high-value care across settings.